SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today that its abstract for a poster on “Multiplex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput System” has been accepted for presentation at the 30th Annual Clinical Virology Symposium, April 27–30 in Daytona Beach, FL. The poster, abstract #1256, was accepted by the organizers of the Clinical Virology Symposium and American Society of Microbiology.
The poster will cover the development progress of Applied BioCode’s new high throughput multiplex system in addition to a 16-plex Gastrointestinal Pathogen Panel that currently is in development. The new BioCode platform utilizes Applied BioCode’s proprietary Barcoded Magnetic Beads (BMB) and fully automates the process of amplification, hybridization and detection for molecular diagnostic assays.
The molecular diagnostic assay for the detection of gastrointestinal (GI) pathogens includes targets for the bacteria (Campylobacter, Clostridium difficile toxin A&B, Salmonella, Shigella, E. coli O157, Enterotoxigenic E.coli, Shiga toxin producing E.coli, Enteroaggregative E. coli, Aeromonas, Vibrio spp.), viruses (norovirus group I/II, adenovirus F, rotavirus A), and parasites (Giardia, Cryptosporidium, Entamoeba histolytica).
Preliminary data generated from the system with the Gastrointestinal Pathogen Panel will be presented by Applied BioCode’s scientific personnel.
About Applied BioCode, Inc.
Applied BioCode is a privately held biotechnology company that develops, manufactures, and markets Barcoded Magnetic Beads (BMB) and detection systems to facilitate development of highly multiplexed nucleic acids or protein detection assays. BMB technology offers up to 4,096 unique digital barcodes for multiplex analysis with unmatched decoding accuracy. It is well suited for clinical diagnostic applications such as detection of infectious agents, drug resistance markers, cancer markers and mutation analysis, as well as for life science research and agricultural testing markets.
Currently, we are in the process of developing multiplex infectious disease detection assays and a user friendly, high throughput system based on proprietary BMB technology for Molecular Diagnostics testing. With dedicated mission on improved patient care, our platform and multiplex assays will provide cost effective, rapid and wide-ranging detection of pathogens that can cause serious and life threatening infections within hospitals and their surrounding communities.
